Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021216573 - SCALABLE, EASY-TO-DEPLOY SYSTEM AND REAGENTS THEREOF FOR CRISPR-ASSOCIATED NUCLEASE-BASED DETECTION OF PATHOGEN GENETIC MATERIAL

Publication Number WO/2021/216573
Publication Date 28.10.2021
International Application No. PCT/US2021/028192
International Filing Date 20.04.2021
IPC
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07H 21/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C07H 21/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
C07K 14/47 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C12N 1/21 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
21modified by introduction of foreign genetic material
C12N 5/10 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12N 15/1003
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
C12N 2310/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
10Type of nucleic acid
20involving clustered regularly interspaced short palindromic repeats [CRISPRs]
C12Q 1/6816
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6813Hybridisation assays
6816characterised by the detection means
G01N 33/54346
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
54313the carrier being characterised by its particulate form
54346Nanoparticles
G01N 33/54388
Applicants
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
Inventors
  • ARIAS GONZALEZ, Carolina
  • ACOSTA-ALVEAR, Diego
  • WILSON, Max
  • KOSIK, Kenneth
  • COSTELLO, Michael
  • PONCE ROJAS, Jose Carlos
Agents
  • ZHU, Suwei
  • HUBER, Linda B.
  • HAYES, Jennifer
  • KESAVAN, Sowmya
  • LEVY, Seth D.
Priority Data
63/012,81020.04.2020US
63/036,02408.06.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SCALABLE, EASY-TO-DEPLOY SYSTEM AND REAGENTS THEREOF FOR CRISPR-ASSOCIATED NUCLEASE-BASED DETECTION OF PATHOGEN GENETIC MATERIAL
(FR) SYSTÈME ÉVOLUTIF, FACILE À DÉPLOYER ET RÉACTIFS ASSOCIÉS POUR LA DÉTECTION À BASE DE NUCLÉASE ASSOCIÉE À CRISPR DE MATÉRIEL GÉNÉTIQUE PATHOGÈNE
Abstract
(EN) Scalable testing of a disease or pathogenic infection is limited by hurdles in cost of reagents, instrument accessibility, availability of highly trained personnel, and large upfront investment. Herein, systems and methods for use of CRISPR-associated nuclease-based, Rugged, Equitable, Scalable Testing (CREST) are provided. CREST pairs reliable polymerase chain reaction (PCR) with low-cost instrumentation without sacrificing detection sensitivity, and allows for a binary interpretation of detection results. A new lysis solution for extraction of nucleic acids and/or protein is also provided and can be used to prepare nucleic acid sample in CREST assay. The systems and reagents disclosed provide for a point-of-care solution to increase distribution of COVID-19 surveillance.
(FR) Le test évolutif d'une maladie ou d'une infection pathogène est limité par des obstacles de coût des réactifs, d'accessibilité aux instruments, de disponibilité de personnel hautement qualifié et d'un investissement initial élevé. L'invention concerne des systèmes et des procédés pour l'utilisation de tests robustes, équitables, évolutifs (CREST) à base de nucléase associé à CRISPR. CREST combine une réaction de polymérase en chaîne (PCR) avec une instrumentation à faible coût sans sacrifier la sensibilité de détection, et permet une interprétation binaire de résultats de détection. L'invention concerne en outre une nouvelle solution de lyse pour l'extraction d'acides nucléiques et/ou de protéine qui peut être utilisée pour préparer un échantillon d'acide nucléique dans un dosage CREST. Les systèmes et les réactifs de l'invention fournissent une solution de point d'intervention pour augmenter la distribution de la surveillance de la COVID-19.
Latest bibliographic data on file with the International Bureau